Here's Why Novo Nordisk Stock Popped Today

Another day and another release of results from a clinical trial from Novo Nordisk (NYSE: NVO). However, this time it's positive news. Here's the lowdown. The pharmaceutical company is best known for semaglutide, which is approved to treat Type 2 diabetes (Wegovy) and, most famously, obesity (Wegovy). It's part of an exciting class of drugs, GLP-1 receptor agonists, which includes Eli Lilly's tirzepatide (approved as Mounjaro for Type 2 Diabetes and Zepbound for obesity).Yesterday's "bad" news from Novo Nordisk came from its Phase 3 trials of oral semaglutide in the early stage of Alzheimer's disease. The trials did not establish the superior efficacy of oral semaglutide over placebo in the trial. I've used inverted commas because the Alzheimer's trial was always a low probability event – a Novo Nordisk executive had reportedly described it as a lottery, and few people expect to win lotteries. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool